Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Open accessThe DOI matches its Crossref record; 64 of the 70 references it cites were found in a registry or an index, and 6 are not checked yet; 19 of the 29 sources its claims cite were checked for support.
Abstract
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK
Verified 2026-10-05 · 6 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Not checked yetcites [2] Routy B, Science 359, 91– 97 (2018). 29097494 source
- Supportedcites [3] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 source
The supplied Abstract passage reports an association between gut microbial composition and clinical response to anti-PD-1 therapy in metastatic melanoma patients. It also reports that transferring responder-associated microbiota improved anti-PD-L1 efficacy in mice, supporting the claim that gut bacteria can modulate response to checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [4] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s concluding passage says the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. The citing sentence states this more broadly and definitively for immune checkpoint blockade in cancer; the paper’s patient findings are limited to melanoma and anti-PD-1 treatment. Page numbers were not provided in our copy. (LLM, conf=0.85)
- Partly supportedcites [5] Frankel AE, Neoplasia 19, 848– 855 (2017). 28923537 PMC5602478 sourceExperimental — accuracy not yet measured
The Introduction reports that gut microbiota affect checkpoint-therapy responses in preclinical mouse models, and the Results find different bacterial species enriched in melanoma patients who responded to treatment. The human findings are associations, however; the paper says the mechanism of immune enhancement by these bacteria in humans remains unknown. Thus it does not establish that gut bacteria modulate treatment response in cancer patients. (LLM, conf=0.84)
- Supportedcites [6] Peters BA, Genome Med 11, 61 (2019). 31597568 PMC6785875 source
The Conclusions state that the pilot study supports the notion that gut microbiota modulate immunotherapy response in melanoma patients. The Background identifies the treatments studied as PD-1 and CTLA-4 checkpoint inhibitors, matching the claim’s reference to immune checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [7] Andrews MC, Nat. Med 27, 1432– 1441 (2021). 34239137 PMC11107795 sourceExperimental — accuracy not yet measured
The Main Text reports that several gut bacterial taxa differed between melanoma patients who did and did not respond to combined checkpoint blockade, with related associations in mouse tumor models (page unavailable). This supports a link between gut bacteria and treatment response, but the patient findings are associations; they do not establish that bacteria modulate response in cancer patients generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“given the known impact of these on ICB response (32)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Partly supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 sourceExperimental — accuracy not yet measured
The Key Points report that antibiotics given within 30 days before immune checkpoint inhibitor therapy were associated with a higher risk of disease refractory to treatment. The claim is broader than the finding: the paper reports an observational association for prior antibiotic use, while its Limitations section says concurrent antibiotic use was not associated with response. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“however, this is not unexpected given the known challenges of isolating associations of specific dietary components from other factors known to affect the gut microbiota in observational human cohorts (33, 34).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [33] Klurfeld DM, Am. J. Physiol. Endocrinol. Metab 315, E1087– E1097 (2018). 30130151 PMC6415710 source
The WORKSHOP SUMMARY ('Focus on human studies of the colonic microbiome') states numerous challenges in characterizing diet effects on the human gut microbiome, including poor adherence, inaccurate characterization of dietary intake/composition, and that human observational studies generally point only to associations, with logistical challenges in large cohort studies. The same summary notes that diets high in protein or fat are necessarily low in carbohydrates, 'making it almost impossible to attribute causality to an individual macronutrient,' and lists nondietary factors (stress, exercise, smoking, coffee, personality) plus marked interindividual variation that must be recorded. The table under 'Choice of species depends on question(s) asked.' adds that cross-sectional studies cannot prove causality and that intake recording is relatively inaccurate. Together these support the paraphrase that isolating specific dietary components from other microbiota-affecting factors in observational human cohorts is challenging. (LLM, conf=0.87)
- Not checked yetcites [34] Makki K, Deehan EC, Walter J, Bäckhed F, Cell Host Microbe 23, 705– 715 (2018). 29902436 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that many of the response-associated bacteria identified in our cohort have known roles in starch degradation and fiber fermentation (25–29)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [25] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E, Gut Microbes 3, 289– 306 (2012). 22572875 PMC3463488 source
The paper’s Firmicutes sections describe starch utilization by Roseburia and Eubacterium rectale and plant-fiber polysaccharide utilization by Roseburia intestinalis and other gut bacteria (page numbers unavailable). The citation supports the bacteria’s known roles; identifying which bacteria were response-associated in the citing authors’ cohort is the citing authors’ own observation. (LLM, conf=0.86)
- Partly supportedcites [26] den Besten G, J. Lipid Res 54, 2325– 2340 (2013). 23821742 PMC3735932 sourceExperimental — accuracy not yet measured
In “The composition of gut microbiota” (page unavailable), the review identifies Bacteroidetes as fermenters of nondigestible carbohydrates, supporting a general role for gut bacteria in fiber fermentation. It does not identify the citing paper’s response-associated bacteria or establish that many of them degrade starch. (LLM, conf=0.84)
- Partly supportedcites [27] Poeker SA, Sci. Rep 8, 4318 (2018). 29531228 PMC5847601 sourceExperimental — accuracy not yet measured
The Results and Discussion describe bacterial responses to dietary fibers and identify taxa involved in fermenting or degrading them, including inulin-degrading Ruminococcaceae and Prevotella fermenting complex polysaccharides. The paper does not establish a role in starch degradation for these bacteria. Which bacteria were identified in the citing authors’ cohort is their own finding, not a finding attributed to this source. (LLM, conf=0.84)
- Partly supportedcites [28] So D, Am. J. Clin. Nutr 107, 965– 983 (2018). 29757343 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says Bifidobacterium and Lactobacillus utilize prebiotic fibers as substrates and discusses their fermentation preferences, supporting the fiber-fermentation part. The paper does not establish starch-degradation roles for many bacteria; its References list a work on Ruminococcus bromii and resistant-starch degradation, but that does not substantiate the broader claim. (LLM, conf=0.82)
- Supportedcites [29] Desai MS, Cell 167, 1339– 1353. e21 (2016). 27863247 PMC5131798 source
The Results describe testing gut bacteria for growth on dietary-fiber polysaccharides and identifying which bacteria use each carbohydrate. The supplemental figure (Additional information; page unavailable) identifies several species as plant-fiber and starch degraders and depicts short-chain fatty acid production from plant fiber. The cited paper supports those functional roles; the statement that the bacteria were response-associated in the citing authors’ cohort is their own framing. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The observed protective effect of dietary fiber intake in relation to PFS and response remained consistent among the subset of patients treated with anti–PD-1 monotherapy, with the exclusion of patients reporting recent antibiotic use given the known impact of these on ICB response (32) (tables S11 and S12).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 source
The citation is attached to the rationale for excluding patients with recent antibiotic use, not to the citing authors’ dietary-fiber findings. The Results report that prior antibiotic therapy was associated with poorer response to immune checkpoint inhibitor treatment; the paper distinguishes this from concurrent antibiotic therapy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 1 with their cited sources checked
Create a free account to see all 52 claims and to verify the 10 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fiber-rich, plant-based diets have the opposite effect, nurturing Bifidobacterium and Lactobacillus, increasing butyrate producers like Roseburia and Eubacterium rectale, and shielding against obesity and insulin resistance via SCFA signaling.15,70,81–83”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have linked deficient SCFA production to conditions such as graft-versus-host disease and poor responses to cancer immunotherapies, spurring interest in SCFA supplementation or diets to restore microbial balance.15,77,88,146,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting a potential benefit of microbially produced SCFAs and an adjuvant role of fiber for ICB7,25.”
From Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, correlations have been drawn across cancer indications and geographical sites between the taxonomic composition of the gut (and to some degree tumor) microbiota, and ICI responses in patients with melanoma and other cancers.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, exposures including medications, especially antibiotics and proton pump inhibitors, and diet that shape the microbiota are associated with ICI responses in patient cohorts and preclinical models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Research works printed but not linked: 1
- H. Mallick A. Rahnavard L. J. McIver S. Ma Y. Zhang L. H. Nguyen T. L. Tickle G. Weingart B. Ren E. H. Schwager S. Chatterjee K. N. Thompson J. E. Wilkinson A. Subramanian Y. Lu L. Waldron J. N. Paulson E. A. Franzosa H. C. Bravo C. Huttenhower Multivariable Association Discovery in Population-scale Meta-omics Studies. bioRxiv 2021.01.20.427420 [Preprint] (2021). .10.1101/2021.01.20.427420 2021.01.20.427420 · doi:10.1101/2021.01.20.427420
Cited by
Items 601–700 of 967
Moomin, A., Gawusu, S., Sidiki, A. I., Tizumah, M. W., Adam, M. K., Adu-Gyamfi, P. K. T., & Mensah, K. B. (2025) · BioMed Research International · doi:10.1155/bmri/5086946 · Cited by 4
Zeng, Z., Zhou, J., Zhang, W., Peng, J., Li, Y., Jin-si-han, E.-E.-M.-B.-K., Wang, H., Lian, S., Feng, C., Xie, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589869 · Cited by 8
Food for Thought: Addressing a Research Gap for Dietary Trials in Hematologic Malignancies
Patel, A. P., Kassam, S., & Shah, U. A. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0141 · Cited by 4
A gut response: Modulating chemotherapy efficacy with microbial metabolites
Bauer, K. C., & Greten, T. F. (2023) · Immunity · doi:10.1016/j.immuni.2023.03.011 · Cited by 4
Fibre intake and supplementation during treatment for haematological malignancies: A scoping review
Andersen, S., Henden, A. S., Staudacher, H. M., Kennedy, G., & Gavin, N. (2023) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13209 · Cited by 5
The microbiome and ovarian cancer: insights, implications, and therapeutic opportunities
Mehra, Y., Chalif, J., Mensah-Bonsu, C., Spakowicz, D. J., O’Malley, D. M., & Chambers, L. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2023.107 · Cited by 5
Microbiome dynamics in immune checkpoint blockade
Kim, C. W., Kim, H.-J., & Lee, H. K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.013 · Cited by 5
Xiang, Y., Zhang, C., Wang, J., Cheng, Y., Wang, K., Wang, L., Tong, Y., & Yan, D. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04686-9 · Cited by 5
Self-citationTamer, F., & Kekilli, M. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15465 · Cited by 7
Exploring the Interplay of Diet, Obesity, Immune Function, and Cancer
Fu, Y., Guo, X., Sun, L., Cui, T., Wang, J., Liu, Y., & Liu, L. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0834 · Cited by 4
Overview on biomarkers for immune oncology drugs
Имянитов, Е. Н., Преображенская, Е. В., & Mitiushkina, N. V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002298 · Cited by 5
Influence of high-fiber diet on ipilimumab-induced gastrointestinal toxicity in metastatic melanoma
Majenka, P., Hoffmann, M., Strobel, S., Rötzer, I., Enk, A. H., & Hassel, J. C. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.026 · Cited by 5
Using gut microorganisms to treat cancer
Seo, Y. D., Ajami, N. J., & Wargo, J. A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02460-y · Cited by 5
Self-citationTIME for Bugs: The Immune Microenvironment and Microbes in Precancer
Bowen, M. B., Helmink, B. A., Wargo, J. A., & Yates, M. S. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0087 · Cited by 5
Self-citationUsyk, M., Hayes, R. B., Knight, R. D., González, A., Li, H., Osman, I., Weber, J. S., & Ahn, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.589761 · Cited by 4
The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis
Ryan, T., Ling, S., Trinh, A., & Segal, J. P. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101945 · Cited by 4
Zhao, B., Zhou, B., Li, Q., Su, C., Ma, J., & Yang, L. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.70006 · Cited by 3
Fibre, microbes and radiotherapy: unravelling the gut’s impact on radiotherapy in cancer
Twhigg, L., Ng, H. M., Glyn, T., Wall, C., & Purcell, R. V. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100174 · Cited by 5
Oral microbiota: Roles and treatment in radiation injury (Review)
Song, J., & Lei, X. (2025) · Oncology Letters · doi:10.3892/ol.2025.15218 · Cited by 3
Immune Landscape of Intrahepatic Cholangiocarcinoma: Evasion and Therapeutic Insights
Porro, N., Spínola-Lasso, E., Marra, F., & Gentilini, A. (2025) · Immuno · doi:10.3390/immuno5030040 · Cited by 4
Shanmukha, K. D., Pasupuleti, V., Yadav, K., Baviskar, S. M., Pradhan, M., Vora, L. K., & Khatri, D. K. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10796-9 · Cited by 9
The Mediating Role of the Gut Microbiome in the Nutritional Prevention of Cancer
Chambial, P., Thakur, N., Kumar, U., & Gupta, S. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.101301 · Cited by 4
Chan, N. S. L., Cross, C., Prestidge, C. A., Wardill, H. R., Bowen, J. M., & Joyce, P. M. (2026) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2610215 · Cited by 5
Chen, X., Zuo, Z., Xiao, B., & Zhao, F. (2026) · Gut · doi:10.1136/gutjnl-2025-337778 · Cited by 5
Wu, Q., Zhou, Y.-R., Chen, Z.-R., Liu, M.-X., Liu, M.-X., Liu, Y.-F., Li, Z., Zhao, Q.-R., Zhang, Y.-Q., Zhang, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105230 · Cited by 5
Self-citationAntohi, A. L., Gheorghiță, A. D., Andronic, O., Pîrcălăbioru, G. G., & Treteanu, A. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062538 · Cited by 7
The microbiome: regulating anti-tumor immunity
Tao, Y.-L., Wu, X.-X., Wang, J.-R., Liu, M., Liu, Y.-N., Lian, Y.-Q., Liang, Z., & Zhu, S.-F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1781872 · Cited by 5
Thu, M. S., Le, H. B. C., Duc, N. P., Mai, V. H., Walker, N., & Hirankarn, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-44743-7 · Cited by 10
Han, W., Li, Q., & Yuan, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802676 · Cited by 4
Elsheikh, M., Ibrahim, M. A., Fares, S., Bhongade, M., Adhem, K., Ramirez-Morales, X. I., Kaseb, A. O., Petrosino, J. F., Hassan, M. M., & Jalal, P. K. (2026) · Cancer Medicine · doi:10.1002/cam4.71738 · Cited by 4
Self-citationUsyk, M., Hayes, R. B., Knight, R. D., Gonzalez, A., Huilin, L. I., Osman, I., Weber, J. S., & Ahn, J. (2026) · Cell · doi:10.1016/j.cell.2026.03.041 · Cited by 8
Gut microbiota and metabolic control of immune checkpoint blockade in cancer
Gladstone, J. L., & Sonnenberg, G. F. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.018 · Cited by 4
Preetam, S., Bora, J., Dutta, S. P., Talukdar, N., Rustagi, S., Thapliyal, S., Malik, S., Choudhary, N., Kumar, D., & Kondaveeti, S. B. (2026) · Infectious Agents and Cancer · doi:10.1186/s13027-026-00767-2 · Cited by 3
Yang, S., Lu, H., Jin, M., Pei, W., Wang, Z., Ni, J., Shi, Y., Zhang, S., Li, Y., Li, C., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.002 · Cited by 7
How gut reactions are shaping cancer treatment
Nogrady, B. (2022) · Nature · doi:10.1038/d41586-022-00933-7 · Cited by 3
Coleman, M., Mascialino, S. J., Panjwani, A., Edwards, E., Sukhatme, V. V., Gavegnano, C., & Sukhatme, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1281744 · Cited by 4
McClanahan, K., Sánchez, P. G., Gant, K., Joyce, J. M., & Braun, A. C. (2024) · Journal of Nutrition Education and Behavior · doi:10.1016/j.jneb.2024.01.008 · Cited by 3
Ebrahimi, H., Battle, D. J., Salgia, N., Zengin, Z. B., Dizman, N., Meza, L. A., Bergerot, C. D., Barragán-Carrillo, R., Hsu, J., Castro, D. V., et al. (2024) · Nutrients · doi:10.3390/nu16111630 · Cited by 3
Zhang, X., Mallick, H., & Rahnavard, A. (2026) · Communications Medicine · doi:10.1038/s43856-026-01612-8 · Cited by 10
Self-citationSpectroscopic secondary structure fingerprint of β-variant of SARS-CoV-2 spike glycoprotein
Mosetti, R., Mancini, T., Bertelà, F., Macis, S., Luchetti, N., Minicozzi, V., Lupi, S., & D’Arco, A. (2025) · European Biophysics Journal · doi:10.1007/s00249-025-01782-8 · Cited by 3
Arima, J., Yoshino, H., Tatarano, S., Mitsuke, A., Osako, Y., Sakaguchi, T., Matsushita, R., Inoguchi, S., Yamada, Y., & Enokida, H. (2025) · Cancer Reports · doi:10.1002/cnr2.70308 · Cited by 6
Role of the microbiota in oncogenesis
Grigorievskaya, Z. V., Николаевна, П. И., Bagirova, N. S., Агинова, В. В., & Kononets, P. V. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-2-129-142 · Cited by 3
Gut microbiota: key facilitator in metastasis of colorectal cancer
Yu, S., Wang, S., Xiong, B., & Peng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1270991 · Cited by 6
Functional regulation of cytotoxic T Cells by gut microbial metabolites
Kim, C. H. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2454002 · Cited by 6
Saikia, T., Patowary, L., Sadhu, P., & Laloo, D. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_15 · Cited by 3
Changing the culture for the future: time to take brain drain in academics seriously
Day, C., Marie, K. L., & Weeraratna, A. T. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.12.002 · Cited by 2
Self-citationGuilds as guides for health vs. disease
Gomes, A. L. C., & Jenq, R. R. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.11.010 · Cited by 2
Self-citationMa, Y., Ghiretti, L., Castellone, V., Mena, P. R., & Rubert, J. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.12.034 · Cited by 2
The role of microbiome in CAR-T cell therapy
Abdel‐Wahab, R., Kerr, T. D., McGrail, D. J., Diab, A. K., & Bentebibel, S.-E. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.015 · Cited by 2
Self-citationDietary impacts on prostate cancer immunotherapy
Duong, L., & Lü, X. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2511472 · Cited by 2
Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., Hlodáková, A., & Soumarová, R. (2025) · Cancers · doi:10.3390/cancers17132238 · Cited by 2
Focus on gut microbes: new direction in cancer treatment
Liao, L., Zeng, M., Liu, D., He, Y., Du, W., & Cao, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1505656 · Cited by 3
McCullough, F. S. W., Cheung, J., & Miller, L. J. (2025) · Nutrients · doi:10.3390/nu17182973 · Cited by 2
Invisible influencers: the tumor microbiome’s impact on immunotherapy in colorectal cancer (CRC)
Omar, T. M., Al-Hussainy, A. F., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Polatova, D., Sameer, H. N., Salih, R. M., Adil, M., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2579656 · Cited by 3
The role of microbiome in immunotherapy: Insights and perspectives
Ye, M., Ju, H., Ren, G., & Hu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.11.001 · Cited by 4
Self-citationZhao, Y., Zhao, Y., Shi, J., Guan, B., Long, M., Sun, Z., Jin, S., Yan, Y., Chang, T., Fu, Y., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1712240 · Cited by 4
Self-citationOpportunities and challenges in applying microbiota to clinical cancer immunotherapy
Jia, D., & Wang, L. (2025) · Trends in Microbiology · doi:10.1016/j.tim.2025.11.011 · Cited by 5
Self-citationFarley, M. J., Scanlon, B., Crichton, M., Bigaran, A., Barnes, A., Hart, N. H., Yates, P. M., Eastgate, M. A., & Alexander, K. E. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01714-x · Cited by 2
Jiang, X., Xu, Y., Shen, B., Ji, Y., Shi, L., Gao, J., & Dong, J. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01256 · Cited by 3
Therapeutic properties of plant-derived prebiotics in melanoma
Kay, E. J., Kazi, M., Burton, J. P., & Parvathy, S. N. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002354 · Cited by 2
Zhu, Y., Liang, X., Li, F., Xu, J., Chen, C., Tang, H., Wang, Y., Li, L., Xing, L., Dong, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27942-6 · Cited by 3
Su, P., Tao, Y., Wang, A., & Xiao, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004476 · Cited by 4
The dietary index for gut microbiota and risk of advanced cardio-kidney-metabolic syndrome
Ji, W., Zhang, Q., Gao, B. X., & Jiang, Y. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-02013-2 · Cited by 3
Rank, M. A., Barroso, D. L., Conn, K. A., Pecak, M., Scandura, M., Hirsch, A. H., Gu, H., Whisner, C. M., Shearer, H., Johnson, D., et al. (2026) · Frontiers in Allergy · doi:10.3389/falgy.2025.1707834 · Cited by 2
Japelj, N., Horvat, N., Jazbar, J., Kerec Kos, M., Pelicon, V., & Knez, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682723 · Cited by 2
Kaźmierczak-Siedlecka, K., Kucharski, R., Stachowska, E., Pelikant‐Małecka, I., Marano, L., Makarewicz, W., Kalinowska, M., Dambrauskas, Z., & Kalinowski, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1732712 · Cited by 2
Yan, J., Qian, L., Chen, S., Karekad, M. M. A., Wu, X., Xu, M., & Xu, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1765550 · Cited by 5
Qian, Z.-Y., Deng, Y., Xi, M., Zhang, X. M., Sun, H., Mao, M., Luo, X.-J., Li, M., Zhang, Q., Chen, B., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1449 · Cited by 2
Self-citationThe lethal symbiont: exploring the pathophysiology of cancer
Nolan, E., Li, L., Giampazolias, E., Ombrato, L., & Malanchi, I. (2026) · Physiological Reviews · doi:10.1152/physrev.00019.2025 · Cited by 2
Relationship Between Gut Microbiota and Cancer Neuro‐Immunity
Wang, D., Cui, R., You, C., Zheng, W., Wang, L., Yang, Y., Yu, H., & Cui, B. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70336 · Cited by 3
Self-citationOrletskaia, V., & Olekhnovich, E. I. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0065 · Cited by 6
Su, X., Li, A., Liu, J., Guo, Y., Yu, H., Yu, J., Wang, R., Garza, D. R., Qu, J., Wen, B., et al. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128539 · Cited by 3
Eysha, M., Fouani, M., Munir, M., Black, M., Long, A., Elchouemi, M., Singh, S., & Abid, M. B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1787954 · Cited by 2
Integration of donor microbiota following FMT correlates with anti-PD-1 response in melanoma
Fessler, J. L., Olm, M. R., Engleman, E. G., & Sonnenburg, J. L. (2026) · Nature Communications · doi:10.1038/s41467-026-73465-7 · Cited by 7
The relationship between gut microbiota and cancer immune response and immunotherapy
Jia, Y., Liu, Y., & Liu, J. Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1833138 · Cited by 2
Molecular studies on the impact of microbiome on anticancer drug resistance
Zhou, K., Lu, P., Xu, H., Wang, L., & Liang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848345 · Cited by 2
Self-citationThe nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology
Boroomand, F., Karimi, M. A., Karimzadeh‐Soureshjani, E., Kiani-Shamsabadi, D., Farhang, F., Mardani, H., & Jafari, A. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01147-8 · Cited by 2
Chambers, L. M., Spakowicz, D. J., Chalif, J., O'Connor, R. M., Kistenfeger, Q., Mehra, Y., Mohssen, M., Abdeen, C. S., Haight, P. J., Nagel, C. I., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.06.016 · Cited by 4
Microbiome and cancer: mechanistic insights, diagnostic potential, and therapeutic strategies
Kumar, V., Chaudhary, A., Gautam, M., Verma, P., & Singh, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1844436 · Cited by 3
Fleischer, A. (2026) · Nutrients · doi:10.3390/nu18142393 · Cited by 2
Chang, M., Wang, Y., Ha, J., Neale, Z. R., Ajami, N. J., Diggs, L. P., Nalin, A. P., Ma, Y., Dong, S., Hoballah, Y. M., et al. (2026) · Nature Materials · doi:10.1038/s41563-026-02690-8 · Cited by 3
Self-citationZheng, F., Zhang, Y., & Zhong-xin, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1890287 · Cited by 2
Trust your gut when it comes to driving CARs
Chelvanambi, M., & Wargo, J. A. (2022) · Med · doi:10.1016/j.medj.2022.04.015 · Cited by 2
Self-citationStem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
Tu, S., Aydın, A. M., Maraboyina, S., Chen, Z., Singh, S. R. K., Gökden, N., & Langford, T. (2023) · Cancers · doi:10.3390/cancers15225385 · Cited by 2
Rithi, A. T., Mitra, A., Banerjee, A., Ilanchoorian, D., & Radhakrishnan, A. (2023) · International Journal of experimental research and review · doi:10.52756/ijerr.2023.v36.025 · Cited by 4
Taylor, M. M., Nelson, K. C., & Dimitriou, F. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.04.005 · Cited by 3
Self-citationUnderstanding the microbiome as a mediator of bladder cancer progression and therapeutic response
Golshani, M., Taylor, J. A., & Woolbright, B. L. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.07.004 · Cited by 4
Recent Advances in Bacterium‐Based Therapeutic Modalities for Melanoma Treatment
Khan, M., Dong, Y., Ullah, R., Li, M., Huang, Q., Hu, Y., Li, Y., & Luo, Z. Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401076 · Cited by 2
Self-citationasmbPLS: biomarker identification and patient survival prediction with multi-omics data
Zhang, R., & Datta, S. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1444054 · Cited by 3
Blacklock, K. B., Donnelly, K. S., Lu, Y., del Pozo, J., Glendinning, L., Polton, G. A., Selmic, L. E., Tanis, J., Killick, D., Parys, M., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6377 · Cited by 5
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 4
Fecal microbiota transplantation as a novel therapeutic strategy for pancreatic cancer
Yamamura, R., & Sonoshita, M. (2025) · Translational and Regulatory Sciences · doi:10.33611/trs.2025-003 · Cited by 3
Wilson, R. P., Rink, L. A., & Tükel, Ç. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10256-4 · Cited by 2
Hu, M., Xu, S., Xu, R., Qi, X., Yu, X., Wang, J., Li, Y., Liu, Y., Xi, G., Yu, J., et al. (2025) · Engineering Microbiology · doi:10.1016/j.engmic.2025.100208 · Cited by 2
Beyond the tumor: the gut microbiome as a key player in immunotherapy efficacy and resistance
Zhao, Y., Liu, W., & Hu, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04315-4 · Cited by 3
Wu, K., Sun, X., Xu, J., Guan, Z., Yuan, W., Bao, L., Zhao, Y., Shan, R., Chen, H., Zhao, C., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1582314 · Cited by 2
The Microbiome in Gastrointestinal Cancers
White, M. G., & Wargo, J. A. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.06.007 · Cited by 2
Self-citationGenetic and environmental reprogramming of the sarcoma epigenome
Grand’Maison, A., Kohrn, R., Omole, E. B., Shah, M., Fiorica, P. N., Sims, J., & Ohm, J. E. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.10.001 · Cited by 3
Interactions Between Microbial Therapeutics and the Endogenous Microbiome
Hallowell, H. A., Gao, A. L., Kelly, K. E., & Suez, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-1463-0_21 · Cited by 2
Gattlen, C., Frank, K. R., Marie, D. N., Trompette, A., Chriqui, L.-E., Hao, Y., Abdelnour, E., González, M., Krueger, T., Dyson, P. J., et al. (2024) · JTCVS Open · doi:10.1016/j.xjon.2024.02.007 · Cited by 2
Metadata
- Authors
- Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., Wong, M. C., Morad, G., Rodgers, T., Badger, J. H., Helmink, B. A., Andrews, M. C., Rodrigues, R. R., Morgun, A., Kim, Y. S., Roszik, J., Hoffman, K. L., Zheng, J., Zhou, Y., Medik, Y. B., Kahn, L. M., Johnson, S., Hudgens, C. W., Wani, K., Gaudreau, P.-O., Harris, A. L., Jamal, M. A., Baruch, E. N., Perez-Guijarro, E., Day, C.-P., Merlino, G., Pazdrak, B., Lochmann, B. S., Szczepaniak-Sloane, R. A., Arora, R., Anderson, J., Zobniw, C. M., Posada, E., Sirmans, E., Simon, J., Haydu, L. E., Burton, E. M., Wang, L., Dang, M., Clise-Dwyer, K., Schneider, S., Chapman, T., Anang, N.-A. A. S., Duncan, S., Toker, J., Malke, J. C., Glitza, I. C., Amaria, R. N., Tawbi, H. A., Diab, A., Wong, M. K., Patel, S. P., Woodman, S. E., Davies, M. A., Ross, M. I., Gershenwald, J. E., Lee, J. E., Hwu, P., Jensen, V., Samuels, Y., Straussman, R., Ajami, N. J., Nelson, K. C., Nezi, L., Petrosino, J. F., Futreal, P. A., Lazar, A. J., Hu, J., Jenq, R. R., Tetzlaff, M. T., Yan, Y., Garrett, W. S., Huttenhower, C., Sharma, P., Watowich, S. S., Allison, J. P., Cohen, L., Trinchieri, G., Daniel, C. R., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- Frederick National Laboratory for Cancer Research (US)
- Oregon State University (US)
- Baylor College of Medicine (US)
- Queen's University (CA)
- The University of Texas Health Science Center at Houston (US)
- Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Harvard University (US)
- Weizmann Institute of Science (IL)
- European Institute of Oncology (IT)
- Columbia University (US)
- University of California, San Francisco (US)
- Broad Institute (US)
- Corresponding author
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Cogdill, Alexandria P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- ORCID
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Vetizou, Marie
- Cogdill, Alexandria P.
- Khan, Md A. Wadud
- Zhang, Xiaotao
- White, Michael G.
- Peterson, Christine B.
- Wong, Matthew C.
- Morad, Golnaz
- Rodgers, Theresa
- Badger, Jonathan H.
- Helmink, Beth A.
- Andrews, Miles C.
- Rodrigues, Richard R.
- Morgun, Andrey
- Kim, Young S.
- Roszik, Jason
- Hoffman, Kristi L.
- Zhou, Yifan
- Medik, Yusra B.
- Kahn, Laura M.
- Johnson, Sarah
- Hudgens, Courtney W.
- Wani, Khalida
- Gaudreau, Pierre-Olivier
- Harris, Angela L.
- Jamal, Mohamed A.
- Baruch, Erez N.
- Perez-Guijarro, Eva
- Day, Chi-Ping
- Merlino, Glenn
- Pazdrak, Barbara
- Lochmann, Brooke S.
- Arora, Reetakshi
- Anderson, Jaime
- Zobniw, Chrystia M.
- Simon, Julie
- Haydu, Lauren E.
- Burton, Elizabeth M.
- Wang, Linghua
- Dang, Minghao
- Clise-Dwyer, Karen
- Schneider, Sarah
- Anang, Nana-Ama A. S.
- Toker, Joseph
- Malke, Jared C.
- Glitza, Isabella C.
- Amaria, Rodabe N.
- Tawbi, Hussein A.
- Diab, Adi
- Wong, Michael K.
- Patel, Sapna P.
- Woodman, Scott E.
- Davies, Michael A.
- Ross, Merrick I.
- Gershenwald, Jeffrey E.
- Lee, Jeffrey E.
- Hwu, Patrick
- Jensen, Vanessa
- Samuels, Yardena
- Straussman, Ravid
- Ajami, Nadim J.
- Nelson, Kelly C.
- Nezi, Luigi
- Petrosino, Joseph F.
- Futreal, P. Andrew
- Lazar, Alexander J.
- Hu, Jianhua
- Jenq, Robert R.
- Tetzlaff, Michael T.
- Yan, Yan
- Garrett, Wendy S.
- Huttenhower, Curtis
- Sharma, Padmanee
- Watowich, Stephanie S.
- Allison, James P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- Venue
- Science
- Published
- 2021-12-24
- Volume
- 374
- Issue
- 6575
- Pages
- 1632-1640
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8970537
- OpenAlex
- W4200001874
- Cited by
- 966
- References
- 70
- Citations by year
- 2026: 236 · 2025: 216 · 2024: 172 · 2023: 212 · 2022: 130
- FWCI
- 46.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (27140)
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P50CA221703, R01CA219896, F32CA260769, U54CA224070, T32CA009599, R25CA203650, P30CA016672, P30CA013696)
- National Institute of Allergy and Infectious Diseases (R56AI109294, R01AI133822, R01AI143886, R01AI109294)
- National Institute of Environmental Health Sciences (P30ES030285)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- dietary fiber, probiotics, gut microbiota, melanoma, immune checkpoint blockade, anti-PD-1 therapy, treatment response, progression-free survival, fecal microbiota, tumor microenvironment, interferon-gamma, cytotoxic T lymphocytes, low-fiber diet
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Progression-Free Survival, Immune Checkpoint Inhibitors, Animals, Dietary Fiber, Fatty Acids, Volatile, Feces, Female, Humans, Immunotherapy, Male, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cohort Studies, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.